221 related articles for article (PubMed ID: 35608857)
1. Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation.
Paljarvi T; Forton J; Luciano S; Herttua K; Fazel S
JAMA Netw Open; 2022 May; 5(5):e2213643. PubMed ID: 35608857
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk of intentional self-harm in montelukast users: an updated Sentinel System analysis using ICD-10 coding.
Apata J; Lyons JG; Bradley MC; Ma Y; Kempner ME; Kim I; Eworuke E; Pennap D; Mosholder A
J Asthma; 2024 Jul; 61(7):653-662. PubMed ID: 38064517
[TBL] [Abstract][Full Text] [Related]
3. Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study.
Glockler-Lauf SD; Finkelstein Y; Zhu J; Feldman LY; To T
J Pediatr; 2019 Jun; 209():176-182.e4. PubMed ID: 30905424
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric Adverse Effects of Montelukast-A Nationwide Cohort Study.
Jordan A; Toennesen LL; Eklöf J; Sivapalan P; Meteran H; Bønnelykke K; Ulrik CS; Stæhr Jensen JU
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2096-2103.e1. PubMed ID: 36948487
[TBL] [Abstract][Full Text] [Related]
5. Impact of a prior authorization policy for montelukast on clinical outcomes for asthma and allergic rhinitis among children and adolescents in a state Medicaid program.
Keast SL; Thompson D; Farmer K; Smith M; Nesser N; Harrison D
J Manag Care Spec Pharm; 2014 Jun; 20(6):612-21. PubMed ID: 24856599
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis.
Virchow JC; Bachert C
Respir Med; 2006 Nov; 100(11):1952-9. PubMed ID: 16626955
[TBL] [Abstract][Full Text] [Related]
7. The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients.
Di Salvo E; Patella V; Casciaro M; Gangemi S
Pulm Pharmacol Ther; 2020 Feb; 60():101875. PubMed ID: 31837440
[TBL] [Abstract][Full Text] [Related]
8. The Risk of Neuropsychiatric Adverse Events With Use of Leukotriene Receptor Antagonists in Patients With Asthma: Analysis of Korea's National Health Insurance Sharing Service Database.
Kim JH; Lee H; Jeong D; Lee JH; Kwon HS; Song WJ; Cho YS; Kim YJ; Shin YW; Kim TB
J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3690-3699.e7. PubMed ID: 37660732
[TBL] [Abstract][Full Text] [Related]
9. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis.
Philip G; Nayak AS; Berger WE; Leynadier F; Vrijens F; Dass SB; Reiss TF
Curr Med Res Opin; 2004 Oct; 20(10):1549-58. PubMed ID: 15462688
[TBL] [Abstract][Full Text] [Related]
10. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study.
Ali MM; O'Brien CE; Cleves MA; Martin BC
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):435-45. PubMed ID: 25683909
[TBL] [Abstract][Full Text] [Related]
11. Treatment with montelukast and antidepressive medication-a symmetry analysis.
Winkel JS; Damkier P; Hallas J; Henriksen DP
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1409-1415. PubMed ID: 30136330
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions affecting treatment adherence in first-line treatment of asthma: An observational study.
Erdem SB; Nacaroglu HT; Can D
Allergol Immunopathol (Madr); 2023; 51(2):11-16. PubMed ID: 36916083
[TBL] [Abstract][Full Text] [Related]
13. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review.
Lo CWH; Pathadka S; Qin SX; Fung LWY; Yan VKC; Yiu HHE; Bloom CI; Wong ICK; Chan EWY
Eur Respir Rev; 2023 Sep; 32(169):. PubMed ID: 37758273
[TBL] [Abstract][Full Text] [Related]
16. FDA warning montelukast 03.2020-Statement of the Austrian working group of pediatric pulmonology and allergology.
Zschocke A; Horak F; Eber E; Frischer T; Simma B; Stetzl W; Riedler J; Szépfalusi Z; Zacharasiewicz A
Wien Klin Wochenschr; 2022 Jan; 134(1-2):86-88. PubMed ID: 34904177
[TBL] [Abstract][Full Text] [Related]
17. Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and/or allergic rhinitis.
Whalley D; Petigara T; Rasouliyan L; Tobe K; Tunceli K
Curr Med Res Opin; 2017 Feb; 33(2):215-223. PubMed ID: 27764975
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study.
Dal Negro R; Piskorz P; Vives R; Guilera M; Sazonov Kocevar V; Badia X
Pharmacoeconomics; 2007; 25(8):665-76. PubMed ID: 17640108
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis.
Kim MK; Lee SY; Park HS; Yoon HJ; Kim SH; Cho YJ; Yoo KH; Lee SK; Kim HK; Park JW; Park HW; Chung JH; Choi BW; Lee BJ; Chang YS; Jo EJ; Lee SY; Cho YS; Jee YK; Lee JM; Jung J; Park CS
Clin Ther; 2018 Jul; 40(7):1096-1107.e1. PubMed ID: 29945738
[TBL] [Abstract][Full Text] [Related]
20. A review of montelukast in the treatment of asthma and allergic rhinitis.
Nayak A
Expert Opin Pharmacother; 2004 Mar; 5(3):679-86. PubMed ID: 15013935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
